‘We’ll Be First With Off-The-Shelf CAR-T,’ Vows Precision Biosciences – And Hopes To Win Over Gene-Editing Skeptics
Aiming To Help Patients Who Fail Auto CAR-Ts
Executive Summary
As it and its competitors have failed on the first test of durability with their allogeneic CAR-T candidates, Precision Biosciences is looking to cross the line in a sub-group of responders – as well as prove the value of its gene-editing platform.
You may also be interested in...
Precision Picks New CEO To Tackle Gene Editing’s Commercial Challenges
Precision is looking ahead to market access challenges for its off-the-shelf CAR-T and in vivo gene-editing therapies.
Beam Therapeutics’ Base-Edited CAR-T Placed On Hold
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.
On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.